We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues

By LabMedica International staff writers
Posted on 13 May 2024
Print article
Image: The HSDFM generates an image where each pixel contains a spectral signature corresponding to tissue composition (Photo courtesy of Jeesong Hwang)
Image: The HSDFM generates an image where each pixel contains a spectral signature corresponding to tissue composition (Photo courtesy of Jeesong Hwang)

Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue. This procedure is typically advised for women with early-stage breast cancer or small tumors, as it conserves more of the breast tissue compared to a mastectomy. After undergoing BCS, it is critical to verify that all cancerous cells have been removed to decide if additional surgery is necessary. This verification involves a tumor margin assessment, which examines the edges of the excised tissue (tumor margins) to check for residual cancer cells. Conventionally, this assessment entails staining the tissue samples with dyes and inspecting them under a microscope to differentiate between healthy and cancer cells. However, new optical imaging techniques have emerged as quicker alternatives for conducting these assessments.

A group of researchers from the United States, including members from the National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA), has introduced hyperspectral dark-field microscopy (HSDFM) as an effective technique to swiftly and accurately distinguish between cancerous and healthy cells and identify various tumor subtypes in breast tissues post-lumpectomy. In HSDFM, tissue samples are exposed to multiple wavelengths of light, and the varying intensity of light scattered by cellular and molecular components is analyzed to create distinctive spectral signatures for each type of tissue. This technique generates two-dimensional images where each pixel holds spectral data across multiple wavelengths, enabling precise identification of tissue composition. This approach specifically tackles the limitations commonly faced in hyperspectral tumor margin imaging techniques, which typically depend on reflectance to collect spectral information from tissue samples.

Reflectance-based imaging techniques often struggle with issues like the uneven absorption of light by biological substances, such as oxyhemoglobin in blood, which can lead to inconsistent spectral signatures from different samples. In their study, the researchers examined HSDFM images of breast lumpectomy specimens from several patients. They employed two machine learning strategies to categorize the pixels by tissue type: a supervised method and an unsupervised method. The supervised method utilized was spectral angle mapping, which involves comparing the spectral signature of each pixel against known spectral signatures of different tumor subtypes and tissue types (like fat, connective tissue, and blood) previously identified via histopathological analysis.

For the unsupervised method, they applied the K-means clustering algorithm, which sorts pixels into clusters based on similarity in their spectral signatures, thereby aiding in the identification of tumor regions without needing prior spectral data or specific tissue type knowledge. The spectral signatures derived from both the supervised and unsupervised methods were similar and effectively pinpointed areas containing invasive ductal carcinoma—the most prevalent form of breast cancer, accounting for 75% of all cases—as well as invasive mucinous carcinoma, a less common type where cancer cells grow in mucus. The results indicate that the unsupervised approach is validated by the supervised method, suggesting that HSDFM imaging data could be instrumental in developing unsupervised algorithms for the quick and accurate detection of cancerous tissues, which is expected to improve post-surgical monitoring and treatment planning in BCS, enabling more timely interventions.

Related Links:
NIST

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.